Skip to main content

Table 1 Design of animal experiments

From: Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway

Group

Dosage per chicken

Number of chickens

Design of animal experiment

Experiment 1

 1

PBS (pH 7.2)

 

200 µL

15

Chickens were orally gavaged with PBS, LB(+) and LB(−) once a day from 11 to 20 days of age

 2

L/LB(+)

5.0 × 108 CFU

200 µL

15

 3

M/LB(+)

5.0 × 109 CFU

15

 4

H/LB(+)

5.0 × 1010 CFU

15

 5

L/LB(−)

5.0 × 108 CFU

200 µL

15

 6

M/LB(−)

5.0 × 109 CFU

15

 7

H/LB(−)

5.0 × 1010 CFU

15

Experiment 2

 1

PBS (pH 7.2)

 

200 µL

15

Chickens were gavaged with LB(+) once a day from 11 to 20 days of age, which was combined with EA from 16 to 20 days of age. All chickens except those in the PBS group were challenged with 50 000 E. tenella sporulated oocysts at 21 days of age

 2

L/EA + L/LB(+)

15.0 mg/kg + 5.0 × 108 CFU

200 µL

15

 3

M/EA + M/LB(+)

30.0 mg/kg + 5.0 × 109 CFU

15

 4

H/EA + H/LB(+)

60.0 mg/kg + 5.0 × 1010 CFU

15

 5

Challenge control

/

/

15

  1. For Experiment 1, each chicken in Group 1 was orally gavaged with PBS (pH 7.2), and those in Groups 2–4 were orally gavaged with a high (5.0 × 1010 CFU in 100 μL of PBS), medium (5.0 × 109 CFU in 100 μL of PBS) or low dose (5.0 × 108 CFU in 100 μL of PBS) of live L. brevis 23017; these groups are abbreviated as the H/LB(+), M/LB(+), and L/LB(+) groups, respectively. Groups 5–7 were orally gavaged with heat-killed bacteria L. brevis 23017 at a high (5.0 × 1010 CFU in 100 μL of PBS), medium (5.0 × 109 CFU in 100 μL of PBS) or low dose (5.0 × 108 CFU in 100 μL of PBS); these groups are abbreviated as H/LB(−), M/LB(−), and L/LB(−), respectively.
  2. For Experiment 2, each chicken in Group 1 was orally gavaged with PBS (pH 7.2), and those in Groups 2–4 were orally gavaged with one of three dosages of LB(+) once a day from 11 to 20 days of age. Additionally, three dosages of EA were administered from 16 to 20 days of age. Group 5 was the control challenge group. All chickens except those in the PBS group were challenged with 50 000 E. tenella sporulated oocysts at 21 days of age.